Design Therapeutics(DSGN)

Focus: Design Therapeutics is a public biotech company focused on drugs targeting nucleotide-repeat expansion disorders, operating from Carlsbad, CA with 201-500 employees. The company maintains a diverse pipeline across oncology, neurology, infectious diseases, cardiovascular, and respiratory indications.

Oncology Neurology Infectious Diseases Cardiovascular

Profile data last refreshed 11h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

201-500

Open Jobs

About Design Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Design Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Pipeline & Clinical Trials

Intervention Technology

Low Back Pain

N/A

Knee OA Brace

Knee Osteoarthritis

N/A

Miraπ

Stroke

Help build intelligence for Design Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading position in rare nucleotide-repeat expansion disorders with first-mover advantage in a specialized niche
Active pipeline with Phase 1-3 programs across multiple therapeutic areas (20 total programs including DT-216P2 for Friedreich Ataxia and DT-168 for Fuchs dystrophy)
Public company status provides equity liquidity and access to capital markets for sustained R&D investment

Watch Out For

Significant cash burn: $49.6M net loss in FY2025 with only $23M cash on hand and declining R&D spend ($44M in FY2025 vs $57M in FY2024)
Zero active job openings at time of analysis; no current hiring activity or department expansion signals

Generated by Claude from Design Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

COMMIT mHealth application

Depression

N/A

Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA1

Ovarian Cancer

N/A

Intervention: Mental Health Technician

Depression

N/A

Active Stimulation

COPD

N/A

Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public He

Carcinoma, Non-Small-Cell Lung

N/A

COMMIT mHealth application

Hiv

N/A

Conventional burger

Cardiometabolic Health

N/A

Cone Beam Computed Tomography

Healthy Ankle

N/A

Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Switching Antiplatelet

Acute Coronary Syndrome

N/A

TURBUHALER®

Asthma

N/A

Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain

Hypertension, Pregnancy-Induced

N/A

Microbiological studies

Bacteremia by Enterobacteriaceae

N/A

Insole and ankle device

Mild Cognitive Impairment (MCI)

N/A

Rehabilitation combined to a digital maintenance program

Post-COVID-19 Syndrome

N/A

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Ca

Healthy Subjects

N/A

ZenctuaryVR+ Interactive Virtual Reality

Palliative Care

N/A

SOONER Video & Kit

Opioid Use

N/A

Endocuff Vision

Colorectal Neoplasms

N/A

Fourth Trimester Mobile Tool

Pregnancy Related

N/A

Verio Pattern Alert® activated

Diabetes Mellitus

N/A

Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in th

Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Coinfected Subjects

N/A

Observational Translational Study

Sarcoma

N/A

Emotion induction using video

Emotion, Expressed

N/A

Brain Computer Interface integrated HandyRehab platform

Stroke

N/A

eADAPT training

Amputation

N/A

Room configuration

Elderly, Frail

N/A

Standard intervention: Offer PrEP choice

Oral Pre-exposure Prophylaxis (PrEP)

N/A

Hemosphere platform® together with the FloTrac Acumen IQ® sensor

Intraoperative Hypotension

N/A

Multicenter Intervention Program to Optimize the Clinical Management of Community-acquired Pneumonia

Community Acquired Pneumonia

N/A

Standard health coaching

Metabolic Syndrome

N/A

Home for Life mobile application

Hip Replacement

N/A

StayOk web application

Mental Health Disorder

N/A

Acoustic Analytic Apps for Smart Telehealth Screening - Creating a Big Data

URTI

N/A

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:

Systemic Autoimmune Diseases

N/A

Peer Visitation Program

Amputation

N/A

experimental foot device

Balance

N/A

Telemonitoring Constant

Chronic Lung Disease

N/A

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: In

Systemic Autoimmune Diseases

N/A

Etanercept Survival in Elderly Population

Psoriasis

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Publications: 2 in PubMed

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

R&D Spend

$44M22%

Net Income

-$50M

Cash

$23M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells.

Nature communications

2025

PMID:39994194

Taste adaptations associated with host specialization in the specialist Drosophila sechellia.

The Journal of experimental biology